menu
    • menu
    [{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"RMC-6236","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"RMC-6236","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"RMC-6236","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.29999999999999999,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ J.P. Morgan"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"RMC-6236","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ J.P. Morgan"},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"RMC-6236","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EQRx \/ Revolution Medicines","highestDevelopmentStatusID":"6","companyTruncated":"EQRx \/ Revolution Medicines"},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"RMC-6236","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EQRx \/ Revolution Medicines","highestDevelopmentStatusID":"6","companyTruncated":"EQRx \/ Revolution Medicines"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"RMC-6236","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Revolution Medicines \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for RMC-6236

    Menu

    RMC-6236

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Revolution Medicines

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Revolution Medicines

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Revolution Medicines to Update RMC-6236 Pancreatic Cancer Program on July 15, 2024

                            Details : RMC-6236 is a small molecule, RAS(ON) multi-selective inhibitor, given orally. It is being investigated for the treatment of pancreatic ductal adenocarcinoma.

                            Brand Name : RMC-6236

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 08, 2024

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Revolution Medicines

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Revolution Medicines Completes Acquisition of EQRx

                            Details : Through the acquisition, Revolution expects to conduct late-stage development of RAS(ON) inhibitor drug candidate pipeline, including RMC-6236, in multiple RAS-driven cancers.

                            Brand Name : RMC-6236

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 09, 2023

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Revolution Medicines

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Revolution Medicines

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More than $1 Billion in Addi...

                            Details : Through the acquisition, Revolution expects to conduct late-stage development of RAS(ON) inhibitor drug candidate pipeline, including RMC-6236, in multiple RAS-driven cancers.

                            Brand Name : RMC-6236

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 01, 2023

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Revolution Medicines

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Revolution Medicines

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Revolution Medicines

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : J.P. Morgan

                            Deal Size : $345.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' O...

                            Details : The net proceeds will be used to fund development of RAS(ON) Inhibitor programs, including clinical development of RMC-6236 and RMC-6291 and advancement of RMC-9805 and RAS Companion Inhibitor programs, including RMC-4630 and RMC-5552 into clinical devel...

                            Brand Name : RMC-6236

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 07, 2023

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : J.P. Morgan

                            Deal Size : $345.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Revolution Medicines

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Revolution Medicines

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : J.P. Morgan

                            Deal Size : $300.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock

                            Details : The net proceeds will be used to fund development of RAS(ON) Inhibitor programs, including clinical development of RMC-6236 and RMC-6291 and advancement of RMC-9805 and RAS Companion Inhibitor programs, including RMC-4630 and RMC-5552 into clinical devel...

                            Brand Name : RMC-6236

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 02, 2023

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : J.P. Morgan

                            Deal Size : $300.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Revolution Medicines

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Revolution Medicines

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of...

                            Details : RMC-6236, is the first oral, direct RAS inhibitor to be deployed against a tumor harboring the KRAS G12D variant, designed to treat patients with cancers driven by a variety of RAS mutations.

                            Brand Name : RMC-6236

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 28, 2022

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Revolution Medicines

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Revolution Medicines

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Resear...

                            Details : These presentations will describe recent research findings regarding Revolution Medicines’ broad pipeline of RAS(ON) Inhibitors currently in development, including RMC-6236 (RASMULTI), RMC-6291 (KRASG12C), RMC-9805 (KRASG12D) and RMC-8839 (KRASG13C).

                            Brand Name : RMC-6236

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 09, 2022

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth